ea0029p1825 | Thyroid cancer | ICEECE2012
Castelblanco E.
, Gallel P.
, Martinez M.
, Barrera L.
, Capel I.
, Moreno P.
, Gimenez G.
, Puig-Domingo M.
, Bella R.
, Porta M.
, Halperin I.
, Lopez S.
, Orellana R.
, Cameselle J.
, Matias-Guiu X.
, Mauricio D.
, Robledo M.
, Maravall J.
Papillary thyroid cancer (PTC) is the most common endocrine malignancy. Its management has not changed significantly in recent decades, and most patients receive the same treatment. Moreover, there are not alternative treatments for low response or aggressive neoplasias. The availability of reliable prognostic markers that would allow the PTC to be identified based on their aggressiveness at the time of diagnosis would derive in an individualized treatment. In a previous study...